Is Immix Biopharma Inc. Common Stock a good investment? Immix Biopharma Inc. Common Stock (IMMX) is currently trading at 7.84 USD. Market analysts have a consensus price target of 23.80 USD. This suggests a potential upside from current levels.
Earnings Schedule: Immix Biopharma Inc. Common Stock is expected to release its next earnings report on March 24, 2027. The market consensus estimate for Forward EPS is -0.95.
No, it does not currently pay a dividend.
Immix Biopharma Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be March 24, 2027. The company currently has a trailing EPS of -0.83.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Community Discussion